References
- Bayer S R, DeCherney A H. Clinical manifestations and treatment of dysfunctional uterine bleeding. J Am Med Assoc 1993; 269: 1823–1828
- Kitawaki J, Kado N, Ishihara H, Koshiba H, Kiataoka Y, Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol 2002; 83: 149–155
- McLachlan R I, Healy D L, Burger H G. Clinical aspects of LHRH analogues in gynaecology: a review. Br J Obstet Gynaecol 1986; 83: 431–454
- Shaw R W. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Fertil Steril 1992; 58: 265–272
- Reichel R P, Schweppe K W. Goserelin (Zoladex) depot in the treatment of endometriosis. Zoladex Endometriosis Study Group. Fertil Steril 1992; 57: 1197–1202
- Miller R M, Frank R A. Zoladex (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy. Br J Obstet Gynaecol 1992; 99: 37–41
- Edmonds D K, Howell R. Can hormone replacement therapy be used during medical therapy of endometriosis?. Br J Obest Gynaecol 1994; 101(Suppl 10)24–26
- Lindsay P C, Shaw R W, Bennink H J, Kicovic C P. The effect of add-back treatment with tibolone (Livial) on patients treated with gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril 1996; 65: 342–348
- Compston J E, Yamaguchi K, Groucher P I, Lindsay P C, Shaw R W. The effects of gonadotropin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 1995; 16: 261–267
- Paoletti A M, Serra G G, Cagnacci A, Vacca A M, Guerriero S, Solla E, Mellis G B. Spontaneous reversibility of bone loss induced by gonadotropin releasing hormone analogue treatment. Fertil Steril 1996; 65: 707–710
- Schlaff W D. Extending the treatment boundaries: Zoladex and add-back. Int J Gynaecol Obstet 1999; 64: 25–31
- Franke H R, van de Weijer P HM, Pennings T MM, van der Mooren M J. Gonadotropin-releasing hormone agonist plus ‘add-back’ hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril 2000; 74: 534–539
- Segura C, Avenin D, Gligorov J, Esteso A, Beerblock K, Emile G, Do Huyen N, Lotz J P. The use of GnRH analogues in early and advanced breast carcinomas. Gynecol Obstet Fertil 2005; 33: 914–919
- Gram I T, Ursin G, Spicer D V, Pike M C. Reversal of GnRH agonist induced reductions in mammographic densities on stopping treatment. Cancer Epidemiol Biomarkers Prev 2001; 10: 1117–1120
- Barbieri R. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992; 166: 740–745
- Van Gorp T, Neven P. Endometrial safety of hormonal replacement therapy: review of the literature. Maturitas 2002; 42: 93–104
- Greene J G. Constructing a standard climacteric scale. Maturitas 1998; 29: 25–31
- Mendez A, Cabanillas F, Echenique M, Malekshamram K, Perez I, Ramos E. Mammographic features and correlation with biopsy findings using 11-gauge stereotactic vacuum-assisted breast biopsy (SVABB). Ann Oncol 2004; 15: 450–454
- Sagsveen M, Farmer J F, Prentice A, Breeze A. Cochrane review of gonadotrophin-releasing hormone analogues for endometriosis; bone mineral density. Cochrane Database Syst Rev 2003, 4, CD001297
- Pierce S J, Gazvani C BM, Farquharson R G. Long-term use of GnRH analogs and hormone replacement therapy in the management of endometriosis; a randomized trial with a 6 year follow-up. Fertil Steril 2000; 74: 964–968
- Chlebowski R T, Hendrix S L, Langer R D, Stefanick M L, Gass M, Lane D, Rodabough R J, Gilligan M A, Cyr M G, Thomson C A, , WHI Investigators, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. J Am Med Assoc 2003; 289: 3243–3253
- Greendale G A, Reboussin B A, Slone S, Wasilauskas C, Pike M C, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003; 95: 30–37